12 Best Healthcare Stocks to Buy According to Analysts

9) Cytokinetics, Incorporated (NASDAQ:CYTK)

Number of Hedge Fund Holders: 61

Average Upside Potential: 64.6%

Cytokinetics, Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company, which focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. Leerink Partners analyst Roanna Ruiz has maintained a bullish stance on the company’s stock, offering a “Buy” rating. The rating stems from factors including Cytokinetics, Incorporated (NASDAQ:CYTK)’s strategic plans and financial stability. The company recently announced its ‘Vision 2030’ plan, articulating a strong 5-year roadmap focusing on significantly enhancing both immediate and future value.

Notably, a key component of these plans is the expected FDA approval and commercial launch of aficamten (afi), a leading asset, in 2025, which can strengthen Cytokinetics, Incorporated (NASDAQ:CYTK)’s position in the hypertrophic cardiomyopathy (HCM) market.  Furthermore, the company seems to be well-positioned financially, with ~$1.3 billion in cash and cash equivalents and investments as of September 30, 2024, aiding the execution of its commercial strategies and pipeline development. The analyst believes that ongoing and upcoming clinical trials throughout various programs support a promising pipeline, further justifying a “Buy” rating for Cytokinetics, Incorporated (NASDAQ:CYTK).

In 2025, Cytokinetics, Incorporated (NASDAQ:CYTK) focuses on continuing the go-to-market plans for aficamten in Germany and expanding commercial readiness activities in Europe in 2025, in preparation for expected approval by the European Medicines Agency (EMA) in H1 2026.